EQS-Adhoc: BB Biotech AG publishes its interim report
|
EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report Ad hoc announcement pursuant to Art. 53 LR October 24, 2025 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2025, which covers the results of its business activities for the first nine months of 2025. Based on the consolidated accounts of BB Biotech AG, net profit for the period ended September 30, 2025, amounted to CHF 106 mn (profit of CHF 16 mn in the same period 2024). In the third quarter a net profit of CHF 448 mn (loss of CHF 157 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio. BB Biotech AG’s interim report as at September 30, 2025, is available under report.bbbiotech.ch/Q325 or www.bbbiotech.com.
Head BB Biotech E-Mail: ir@bbbiotech.com Media Relations
www.bbbiotech.com
Company profile End of Inside Information
24-Oct-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | info@bbbiotech.com |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
| EQS News ID: | 2217330 |
| End of Announcement | EQS News Service |
|
|
2217330 24-Oct-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 669,48 | 683,90 | 0,00 | 1,28 | 0,57 | 119,28 | 0,00 | |
| EBITDA1,2 | 624,04 | 637,31 | -390,46 | -361,02 | -222,29 | 86,01 | 0,00 | |
| EBITDA-Margin3 | 93,21 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 72,11 | 0,00 | |
| EBIT1,4 | 624,04 | 637,31 | -390,46 | -361,02 | -222,29 | 86,01 | 0,00 | |
| EBIT-Margin5 | 93,21 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 72,11 | 0,00 | |
| Net Profit (Loss)1 | 622,84 | 637,24 | -390,53 | -362,83 | -222,41 | 80,66 | 0,00 | |
| Net-Margin6 | 93,03 | 93,18 | 0,00 | -28.346,09 | -39.019,30 | 67,62 | 0,00 | |
| Cashflow1,7 | 197,69 | 241,97 | -91,44 | 234,37 | 234,97 | 323,67 | 0,00 | |
| Earnings per share8 | 11,24 | 11,51 | -7,05 | -6,59 | -4,05 | 1,47 | 1,60 | |
| Dividend per share8 | 3,20 | 3,32 | 3,67 | 2,88 | 2,10 | 1,91 | 1,95 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| BB Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0NFN3 | CH0038389992 | AG | 2.725,68 Mio € | 10.12.1997 | Kaufen | 8FVCMJWM+W3 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 28,11 | 14,55 | 1,93 | -222,62 | 1,14 | 8,42 | 22,85 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 2,10 | 1,91 | 1,95 | 3,96% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 19.03.2026 | 24.04.2026 | 25.07.2025 | 24.10.2025 | 20.02.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +15,31% | +36,31% | +32,08% | +21,93% | +935,79% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
